From Nasdaq: 2025-04-26 00:21:00

Medtronic plc has received FDA approval for the OmniaSecure defibrillation lead, designed for placement in the right ventricle. This lead connects to an implantable defibrillator to treat life-threatening heart rhythm issues in adults and adolescents. The company is also exploring placing the lead in the left bundle branch area, showing promising results with 100% defibrillation success. This innovation in electrophysiology could offer physiologic pacing to mimic the heart’s natural conduction system. Global use of the OmniaSecure lead in the LBB area is still investigational, pending FDA approval.



Read more at Nasdaq: Medtronic Secures FDA Approval For OmniaSecure Defibrillation Lead In Right Ventricle Placement